- Human pathology

Home > A. Molecular pathology > Targeted therapy > Small molecules > abemaciclib


Wednesday 14 December 2016



Abemaciclib is a CDK inhibitor selective for CDK4 and CDK6.

It is an investigational drug for various types of cancer developed by Eli Lilly. It was designated as a breakthrough therapy by the U.S. Food and Drug Administration in October 2015.

See also

- CDK4/6 inhibitors